In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
How HIV long-term survivors contribute to a better future for everyone
Our esteem for their HIV activism—from the red carpet to beyond—is a constant.
Honoring 30 Years at NMAC
For this special issue on aging and HIV, we spoke to a coalition called the HIV+Aging Research Project—Palm Springs (HARP-PS).
Prevention Access Campaign builds on its success with a new executive director of North America.
A look at September issues from the POZ archives
Two HIV researchers discuss their recent books on gay men and HIV-positive women.
Here are some important dates in AIDS history.
POZ contributing writer Shawn Decker shares his journey from being a kid with no real treatment options to now.
Andrew Spieldenner, PhD, chair of the U.S. People Living with HIV Caucus, explores the concept of gratitude in the HIV field.
Starting Symtuza quickly after HIV diagnosis is tied to high viral suppression.
Many women on HIV treatment are at risk of developing a detectable viral load.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.
Final results from the PARTNER 2 study of gay and bi men confirm that undetectable equals untransmittable.
CCR5-blocking antibody leads to long-term HIV suppression
A French man with HIV transmitted the virus to his partner while off meds during a cure trial.
Black women have a HIV rate 15 times higher than white women.
LaTrischa Miles encourages women to engage in their health care.
Read the digital edition!